Abstract | BACKGROUND: OBJECTIVE: METHODS: Patients received subantimicrobial doses of doxycycline twice daily plus metronidazole (n = 20) or placebo plus metronidazole (n = 20) for 12 weeks. Subantimicrobial-dose doxycycline or placebo monotherapy continued for 4 weeks. The primary efficacy measure was change from baseline in total inflammatory lesions at weeks 2 and 16. RESULTS: Total inflammatory lesions were reduced significantly (P =.048) by week 4 and by all subsequent visits in the subantimicrobial-dose doxycycline/ metronidazole group compared with placebo/ metronidazole. Changes from baseline increased over time and were maintained during subantimicrobial-dose doxycycline monotherapy. CONCLUSION: Adjunctive use of subantimicrobial dose doxycycline significantly reduced the clinical signs of rosacea compared with metronidazole alone and may be useful maintenance monotherapy.
|
Authors | Jorge Sanchez, Aida Lugo Somolinos, Pablo I Almodóvar, Guy Webster, Mark Bradshaw, Christopher Powala |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 53
Issue 5
Pg. 791-7
(Nov 2005)
ISSN: 1097-6787 [Electronic] United States |
PMID | 16243127
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Infective Agents
- Tablets
- Metronidazole
- Doxycycline
|
Topics |
- Administration, Topical
- Adult
- Anti-Infective Agents
(administration & dosage)
- Double-Blind Method
- Doxycycline
(administration & dosage, analogs & derivatives)
- Drug Therapy, Combination
- Female
- Humans
- Male
- Metronidazole
(administration & dosage)
- Rosacea
(drug therapy)
- Tablets
|